Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Miyake, Makito ^a   Lawton, Adrienne ^a   Goodison, Steve ^b   Urquidi, Virginia ^b   Gomes Giacoia, Evan ^a   Zhang, Ge ^a   Ross, Shanti ^a   Kim, Jeongsoon ^a   Rosser, Charles J ^a,b  

^a ORLANDO HEALTH   (United States)

^b Nonagen Bioscience Corp   (United States)

Author keywords

Bladder Cancer; Chemokine Ligand 1 (CXCL1); Tumor Grade; Tumor Stage

Indexed keywords

CXCL1 CHEMOKINE; CXCL1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; SCORING SYSTEM; BIOSYNTHESIS; BLADDER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; TRANSITIONAL CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHEMOKINE CXCL1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84879486439     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-322     Document Type: Article

References (31)

1. Moll NM, Cossoy MB, Fisher E, Staugaitis SM, Tucky BH, Rietsch AM, Chang A, Fox RJ, Trapp BD, Ransohoff RM. Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 2009, 66:44-53. 10.1001/archneurol.2008.512, 2792736, 19139298.
2. Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol 2001, 69:513-521.
3. Hembruff SL, Cheng N. Chemokine signaling in cancer: implications on the tumor microenvironment and therapeutic targeting. Cancer Ther. 2009, 7:254-267. 2907742, 20651940.
4. Hannelien V, Karel G, Jo VD, Sofie S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta 1825, 2012:117-129.
5. Verbeke H, Struyf S, Laureys G, Van Damme J. The expression and role of CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev 2011, 22:345-358. 10.1016/j.cytogfr.2011.09.002, 22000992.
6. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002, 72:9-18. 2668262, 12101257.
7. Vazquez-Martin A, Colomer R, Menendez JA. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer 2007, 43:1117-1124. 10.1016/j.ejca.2007.01.037, 17379503.
8. Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R, Bieche I. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 2008, 8:41. 10.1186/1471-2407-8-41, 2267801, 18248671.
9. Engl T, Relja B, Blumenberg C, Müller I, Ringel EM, Beecken WD, Jonas D, Blaheta RA. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 2006, 78:1784-1793. 10.1016/j.lfs.2005.08.019, 16263140.
10. Eck M, Schmausser B, Scheller K, Brändlein S, Müller-Hermelink HK. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol 2003, 134:508-515. 10.1111/j.1365-2249.2003.02305.x, 1808898, 14632759.
11. Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, Cocco A, Cheng L. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005, 11:6512-6519. 10.1158/1078-0432.CCR-05-0891, 16166427.
12. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
13. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009, 374:239-249. 10.1016/S0140-6736(09)60491-8, 19520422.
14. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H, Böhle A. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011, 186:2158-2167. 10.1016/j.juro.2011.07.076, 22014799.
15. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA. European Association of Urology (EAU) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011, 59:1009-1018. 10.1016/j.eururo.2011.03.023, 21454009, European Association of Urology (EAU).
16. Yang H, Gu J, Lin X, Grossman HB, Ye Y, Dinney CP, Wu X. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 2008, 14:2236-2244. 10.1158/1078-0432.CCR-07-1670, 18381966.
17. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005, 23:5746-5756. 10.1200/JCO.2005.01.598, 16110031.
18. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, et al. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 2005, 175:5351-5357.
19. Baird AM, Gray SG, O'Byrne KJ. Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. PLoS One 2011, 27:6.
20. Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, Grossman HB, Dinney CP. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 2001, 8:9-15.
21. Reis ST, Leite KR, Piovesan LF, Pontes-Junior J, Viana NI, Abe DK, Crippa A, Moura CM, Adonias SP, Srougi M, Dall'Oglio MF. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of bladder cancer. BMC Urol 2012, 12:18. 10.1186/1471-2490-12-18, 3424138, 22695075.
22. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 2000, 60:2290-2299.
23. Kawanishi H, Matsui Y, Ito M, Watanabe J, Takahashi T, Nishizawa K, Nishiyama H, Kamoto T, Mikami Y, Tanaka Y, Jung G, Akiyama H, Nobumasa H, Guilford P, Reeve A, Okuno Y, Tsujimoto G, Nakamura E, Ogawa O. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin Cancer Res 2008, 14:2579-2587. 10.1158/1078-0432.CCR-07-1922, 18451219.
24. Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, Lin KH. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann Oncol 2011, 22:2267-2276. 10.1093/annonc/mdq739, 21343381.
25. Bièche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L, Guinebretière JM, Burlinchon S, Lidereau R, Lazennec G. CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 2007, 14:1039-1052. 10.1677/erc.1.01301, 18045955.
26. Middleman BR, Friedman M, Lawson DH, DeRose PB, Cohen C. Melanoma growth stimulatory activity in primary malignant melanoma: prognostic significance. Mod Pathol 2002, 15:532-537. 10.1038/modpathol.3880559, 12011258.
27. Luan J, Shattuck-Brandt R, Haghnegahdar H, Owen JD, Strieter R, Burdick M, Nirodi C, Beauchamp D, Johnson KN, Richmond A. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 1997, 62:588-597.
28. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006, 24:778-789. 10.1200/JCO.2005.03.2375, 16432078.
29. Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmström PU, de la Torre M, Wester K, Allory Y, Vordos D, Caillault A, Radvanyi F, Hein AM, Jensen JL, Jensen KM, Marcussen N, Orntoft TF. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007, 13:3545-3551. 10.1158/1078-0432.CCR-06-2940, 17575217.
30. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 2010, 28:2660-2667. 10.1200/JCO.2009.25.0977, 20421545.
31. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6. 1635162, 15068665.